Sino Biopharmaceutical Limited SBMFF
0.67 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:00 PM EST
0.6509 Day range 0.6509
0.593 52-week range 0.891
- YTD
- -23.74%
- 1 year
- -22.85%
- Market cap
- 11.83B
- EPS (ttm)
- 0.02
- P/E ratio
- 33.25
- YTD return
- -23.74%
- 1-year return
- -22.85%
- Volume
- 1.00K
- Avg volume
- 595
- Open
- 0.6509
- Previous close
- 0.665
- Day's range
- 0.6509 – 0.6509
- 52-week range
- 0.593 – 0.891
- Earnings date
- Aug 26, 2026
2Y +0.2420 (+57.21%)
Next earnings
Aug 26, 2026
Expected Aug 26, 2026. Consensus EPS estimate 0.01766.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 26, 2026 | Jun 30, 2026 | 0.01766 | — | — | — |
| Mar 26, 2026 | Mar 31, 2026 | 0.00858 | 0.00143 | -0.01 | -83.33% |
| Mar 26, 2026 | Dec 31, 2025 | 0.00858 | 0.00143 | -0.01 | -83.33% |
| Aug 18, 2025 | Jun 30, 2025 | 0.01675 | 0.02624 | +0.01 | +56.66% |
| Mar 20, 2025 | Mar 31, 2025 | 0.01096 | 0.00411 | -0.01 | -62.50% |
| Dec 31, 2024 | Dec 31, 2024 | — | 0.00182 | — | — |
News
Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs 
AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal 
Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion 
Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln 
Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea
Your note
Sign in to keep a note on SBMFF — it syncs with the Stock Master app.